Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mutations in DPD-coding gene (DPYD) were shown to increase the risk of severe toxicity in FP-treated cancer patients.
|
19288105 |
2009 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
|
30348537 |
2018 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Deficiency in human DPD is associated with autosomal recessive disease, thymine-uraciluria, and with severe 5-fluorouracil toxicity in cancer patients.
|
16556484 |
2007 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
1,4-DHP is a potent Voltage-Gated Calcium Channel (VGCC) antagonist derivative which acts as an anti-hypertensive, anti- anginal, anti-tumor, anti-inflammatory, anti-tubercular, anti-cancer, anti-hyperplasia, anti-mutagenic, anti-dyslipidemic, and anti-ulcer agent.
|
31735158 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Methylation was detected in five of five DPD-deficient volunteers and in three of five of the DPD-deficient cancer patient samples.
|
16361556 |
2005 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Intratumoral DPD mRNA expression level in pancreatic cancer was significantly higher than the other malignancies.
|
18309485 |
2008 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A DPD-deficient phenotype among cancer patients, which has posed a serious problem in 5FU-based chemotherapy, was reported to be in part ascribed to germline mutations in dihydropyrimidine dehydrogenase (DPYD) gene.
|
11267945 |
2001 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A polymorphism that disrupts a putative gamma-interferon response element was identified in a cancer patient with reduced DPD activity and severe 5FU toxicity.
|
10777676 |
2000 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
|
14635116 |
2003 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Several studies have demonstrated the clinical importance of DPD in cancer patients, suggesting that the efficacy of 5-FU may be related to DPD activity in tumor tissue.
|
10953310 |
2000 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
For example, the presence of dihydropyrimidine dehydrogenase gene (DPYD) polymorphisms in cancer patients may lead to adverse effects when adopting fluoropyrimidine-based therapies.
|
28430339 |
2017 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This review covers a wide range of techniques available to establish DPD status in patients with cancer.
|
17241513 |
2006 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
|
16815558 |
2006 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Recently, many clinical studies have demonstrated that UFT is effective for cancer with a low activity of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD).
|
15868929 |
2005 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Complete or partial deficiency of DPD activity has been demonstrated to induce severe toxicities in cancer patients treated with fluoropyrimidine therapy.
|
23585145 |
2013 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High grade malignancy is significantly associated with higher expression of TS, OPRT and DPD in thymic epithelial tumors.
|
21550686 |
2011 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The Indian cancer patient demonstrated reduced DPD activity (0.11 nmol/min/mg protein) and severe 5-FU toxicities commonly associated with DPD deficiency.
|
16421754 |
2006 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In 400 patients that were diagnosed with cancer and were eligible for 5-FU treatment, 14 patients were found to be heterozygous for the splice-site mutation DPYD IVS14+1G>A, which corresponds to a population frequency of 3.5%.
|
19822137 |
2010 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, increased interest has been focused on the biological roles of TS and DPD as the independent prognostic factors as well as responsive determinants for cancer patients with 5-FU based therapy.
|
19697054 |
2010 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The role of polymorphisms in specific enzymes, such as thiopurine S-methyltransferases (TPMT), dihydropyrimidine dehydrogenase (DPD), aldehyde dehydrogenases (ALDH), glutathione S-transferases (GST), uridine diphosphate glucuronosyl-transferases (UGTs) and cytochrome P450 (CYP 450) enzymes in cancer therapy are discussed in this review.
|
9893619 |
1998 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Thymidine phosphorylase (TP), thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) have been indicated as possible predictive markers for epithelial malignancies.
|
14702180 |
2004 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Moreover, breast cancer was characterized by high TS activity and lung cancer by high DPD activity as compared with gastric and colon cancers, and their high activity levels may influence to the effectiveness of 5-fluorouracil against cancers of these organs.
|
14612954 |
2003 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The aim of this study was to validate, in a routine clinical setting, a simple and rapid method to determine the DPD status in a subset of cancer patients, all presenting with life-threatening toxicities following 5-FU or capecitabine intake.
|
17038885 |
2006 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies.
|
27399164 |
2016 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
DPD activity is highly variable in cancer populations, and this variation may influence the antitumor efficacy of 5-fluorouracil.
|
10499634 |
1999 |